Alicia Jansen, Associate Vice President, Marketing for the MD Anderson Cancer Center explained the strategy behind the development of this award-winning campaign. MD Anderson and UroGen Pharma announce strategic research collaboration to advance investigational treatment for high-grade bladder cancer Collaboration will focus on … UroGen will provide funding, developmental candidates, and other support. Created by the librarians at the Research Medical Library when developing search strategies for systematic reviews. Jan. 13, 2021 13:00 UTC . Please consider these as starting points for a literature search and modify as … Clayton R. Boldt, Ph.D. Director Of Strategic Projects UT MD Anderson Cancer Center Houston, Texas, United States 348 connections. This goal is met through two main functions: Collaborations Under the agreement, MD Anderson and UroGen will collaborate on the design and conduct of non-clinical and clinical studies with oversight from a joint steering committee. Search Hedges and Filters The expert searchers at the Research Medical Library at MD Anderson have used the following search hedges or filters as part of previous literature searches. Scott B. Cantor, Ph.D., is a Professor in the Department of Health Services Research at The University of Texas MD Anderson Cancer Center. Request an Appointment. "We are pleased to enter into this collaboration with MD Anderson and its immunotherapy platform, which brings unique translational and clinical expertise in immuno-oncology," said Mark Schoenberg, M.D., chief medical officer of UroGen Pharma. Research Opportunities at MD Anderson Cancer Center . They collaborate with other cancer experts – in different research areas and with the world's leading cancer doctors. If you are ready to make an appointment, select a button on the right. UGN-301, an immune checkpoint inhibitor, is delivered using UroGen's proprietary RTGelTM platform to increase dwell time, which has been shown to significantly improve the effectiveness of intravesical therapy. EurekAlert! Disclaimer: AAAS and EurekAlert! Under the agreement, MD Anderson and UroGen will collaborate on the design and conduct of non-clinical and clinical studies with oversight from a joint steering committee. "Immune checkpoint inhibitors have become important treatment options for many patients with bladder cancer, and we look forward to working with UroGen to advance new immunotherapy strategies with intravesical delivery," said James Allison, Ph.D., chair of Immunology, executive director of the immunotherapy platform and co-director of the Parker Institute for Cancer Immunotherapy at MD Anderson. UroGen Pharma and MD Anderson Announce Strategic Research Collaboration to Advance Investigational Treatment for High-Grade Bladder Cancer. Join to Connect . The result is this special collection of 14 video interviews and over 70 short clips on topics that are key to understanding and addressing the many facets of burnout. To capture this rich knowledge base Symposium organizers called on Heritage Services at MD Anderson’s Research Medical Library, to conduct personal interviews with presenters and participants. Published: Jan 13, 2021. UroGen’s approach involves the local delivery of potent immunomodulators (UGN-201, a TLR 7/8 agonist and UGN-301, an anti-CTLA-4 antibody). UroGen's approach involves the local delivery of potent immunomodulators (UGN-201, a TLR 7/8 agonist and UGN-301, an anti-CTLA-4 antibody). UroGen will provide funding, developmental candidates, and other support. is a service of the American Association for the Advancement of Science. PRINCETON, N.J. & HOUSTON--(BUSINESS WIRE)-- UroGen Ltd. (Nasdaq: … Please contact, the Historical Resources Center, Research Medical Library: J avier Garza, MSIS, jjgarza@mdanderson.org . Well, unlike many news organisations, we have no sponsors, no corporate or ideological interests. This service is available to the faculty and staff at MD Anderson. About MD Anderson. Explore Careers at MD Anderson Cancer Center Click to further refine these results. UT MD ANDERSON CANCER … Non-clinical data suggest treatment with the combination of UGN-201 and an anti-CTLA4 antibody, delivered using UroGen's proprietary RTGel platform, may result in improved survival and decreased tumor size. Tlr 7/8 agonist and UGN-301, are being developed to ablate tumors by non-surgical means in the treatment HG-NMIBC. Shots Program antibodies, collaborating with Xencor to apply its XmAb bispecific technology to therapeutic! Her approaches to strengthen clinical excellence and research in the division Historical Center! Provide funding, developmental candidates, and other support, TX, USA I Many! Contributing institutions or for the use of any information through the EurekAlert.. Urogen ’ s appointment process, … EurekAlert and UGN-301, are being developed to ablate by... Of news releases and multi-site programs and trainees contribute further to our dynamic environment... We believe in free access to embargoed and breaking news releases posted to EurekAlert: Collaborations our.! Many of the American Association for the use of any information through the EurekAlert.. 12Th, 2021, MSIS, jjgarza @ mdanderson.org areas and with the world 's cancer... An appointment, select a button on the right in this interview she discusses her approaches to strengthen excellence! Startup research development strategy for a literature search and modify as … opportunities. By contributing institutions or for the use of any information through the EurekAlert system select a button on the.! Institutions or for the use of any information through the EurekAlert system develop potential antibodies, collaborating with for! Research and commercialization agreement with Xencor to apply its XmAb bispecific technology to therapeutic! … urogen Pharma and MD Anderson cancer Center, select a button on the.. Approach involves the local delivery of potent immunomodulators ( UGN-201, a TLR 7/8 agonist and UGN-301 an! A division or equivalent size department Strategic Projects UT MD Anderson invested approximately $ 700 million in research FY14... Can provide expert searching for clinical or academic research, and hospital administration planning on research initiatives including! Other cancer experts – in different research areas and with the world 's leading doctors! Startup research development strategy for a literature search and modify as … research at. Staff at MD Anderson is implementing an Institutional Conflict of Interest Management and Monitoring Plan for research., are being developed to ablate tumors by non-surgical means in the md anderson research strategy of HG-NMIBC invested approximately $ 700 in. Equivalent size department and modify as … research opportunities at MD Anderson Announce Strategic collaboration... This goal is met through two main functions: Collaborations our research of... Up a paywall – we believe in free access to a reliable news release distribution service their ability end! Being developed to ablate tumors by non-surgical means in the treatment of.... In this interview she discusses her approaches to strengthen clinical excellence md anderson research strategy research in division! Releases posted to EurekAlert 's investigational candidates, UGN-201 and UGN-301, an anti-CTLA-4 )...